Agunmɛkpo ɖé lɛ tíìn bɔ è sixu dó gbɔ azɔn na nú kansɛ́n e nɔ gbò azin ɔ é, bɔ é na sín kansɛ́n ɔ sín ninɔmɛ kpo é nyla sɔ é kpo, lanmɛ syɛn hunsin tɔn kpo nǔ e jló azinzɔnnɔ ɔ kpo wu.
Agunmɛji e è nɔ zán hwɛhwɛ lɛ é ɖé lɛ ɖíe:
1. Nukúnkpénúmɛ ɖ'ayǐ tɔn: Ali enɛ nɔ byɔ ɖɔ è ni nɔ kpɔ́n kansɛ́n ɔ ganji, bo nɔ ba dò nú azɔn tɔn hwɛhwɛ, bo nɔ lɛ́ bló nǔ ɖevo lɛ, é nyí azɔn ɔ jí wɛ è nɔ bɛ́ azɔngban dó tlolo ǎ.
É sixu nyɔ́ nú sunnu ɖěɖee ɖó kansɛ́ɛ́n e nɔ hu mɛ ǎ lɛ é.
2. Alɔwliwli: Alɔwliwli e nɔ ɖè nyɔnuví e ɖò afɔgómɛ é sín lanmɛ é wɛ nyí prostatectomy.
È sixu bló gbɔn avɔnyaɖiɖa e è nɔ bló ɖò ali nu é alǒ laparoscopie (e è nɔ zán nǔ ɖěɖee è nɔ vún kpɛví kpɛví dó bló nǔ lɛ é kpo azɔwanú bunɔ lɛ kpo dó bló é) gblamɛ.
3. Azɔnkwín e è nɔ dó mɛ wu é: Azɔnkwín enɛ nɔ zán hlɔnhlɔn syɛnsyɛn ɖé bo nɔ hu kansɛ́ɛ́zɔn lɛ.
È sixu zé dó lanmɛ nú mɛ (gbigbɔ e ɖò agbaza ɔ gudo é ɖé mɛ) alǒ è sixu zé dó lanmɛ nú mɛ (gbigbɔ e è sɔ́ ɖó fí e nǔ dó é ɖè bɔ é sɛkpɔ nǔ e ɖò lanmɛ nú mɛ é é)
4. Azɔn e è nɔ ylɔ ɖɔ hormone therapy é: Azɔn enɛ nɔ ɖè sunnu sín lanmɛsínsínsín (androgens) e ɖò agbaza mɛ lɛ é kpò, bɔ enɛ sixu zɔ́n bɔ kansɛ́ɛzɔn e nɔ nyí afɔnasin tɔn é na ɖekpo alǒ na ɖó te.
È sixu zán éɖokponɔ alǒ é sixu nyí nǔwiwa ɖé bɔ è na zán xá nǔ ɖevo lɛ.
5. Chemotherapy: Wlɛnwín enɛ nɔ zán amasin lɛ bo nɔ hu kansɛ́ɛ́li lɛ.
È sixu zán dó azɔkan gblegble e gbakpé fí ɖevo lɛ ɖò agbaza mɛ é wu.
6. Azɔnkwín zinzan: Azɔnkwín zinzan enɛ nɔ d'alɔ lanmɛ nɔ cyɔn alɔ mɛ jí bɔ é nɔ fun ahwan xá kansɛ́ɛ.
È sixu zán dó azɔkan gblegble e yì nukɔn bɔ è ma ko kpéwú bo gbɔ azɔn na ǎ é wu.
7. Azɔn e è nɔ dó kpé nǔ wu tawun lɛ é: Azɔn enɛ nɔ kpé nǔ wu tawun dó nǔwukpikpé nùɖé lɛ tɔn alǒ nǔwukpikpé nùɖé lɛ tɔn jí bo nɔ d'alɔ kansɛ́ɛzɔn lɛ bɔ ye nɔ sù bo nɔ nɔ gbɛ̀.
È sixu zán dó azɔkan gblegble e yì nukɔn bɔ è ma ko kpéwú bo gbɔ azɔn na ǎ é wu.
È sixu zán dó azinzɔnnɔ e ɖó kansɛ́n e nɔ gbò kpò ɖò azinɔnnɔkwín ɔ mɛ é wu alǒ kansɛ́n e lɛ́ fɔ́n ɖò amasin ɖevo lɛ zinzan gudo é wu.
9. (HIFU): Alɔkpà enɛ nɔ zán jɔhɔn e nɔ xò ɖò fí línlín lɛ é dó dó zo nú kansɛ́ɛzɔn lɛ bo sú kún tɔn dó.
È sixu zán dó azinzɔnnɔ e ɖó kansɛ́n e nɔ gbò kpò ɖò azinɔnnɔkwín ɔ mɛ é wu alǒ kansɛ́n e lɛ́ fɔ́n ɖò amasin ɖevo lɛ zinzan gudo é wu.
10. Nukúnkpénúmɛ kpo nukúnɖiɖo kpo: Ali enɛ nɔ byɔ ɖɔ è ni nɔ kpɔ́n kansɛ́n ɔ ganji, bo nɔ yì ba do nú mɛ hwɛhwɛ, bo nɔ lɛ́ bló nǔ ɖevo lɛ, amɔ̌, è nɔ bɛ́ amasin ɔ hwenu e wuntun lɛ jɛ wěxo é ǎ.
É sixu nyɔ́ nú sunnu mɛxomɔ ɖěɖee ɖò kansɛ́n e nɔ ɖò nukɔn yì wɛ é jɛ wɛ, bo nɔ ɖò nukɔn yì wɛ kpɛɖé kpɛɖé lɛ é kpo mɛ ɖěɖee ɖò azɔn syɛnsyɛn ɖevo lɛ jɛ wɛ lɛ é kpo.
É ɖò taji ɖɔ è ni ɖɔ xó dó nǔ ɖěɖee è sixu wà bo na dó gbɔ azɔn na é bǐ jí xá dotóo ɖé, bonu é na tuùn nǔ e na nyɔ́ hugǎn ɖò ninɔmɛ ɖokpo ɖokpo mɛ é.
Wang Y, Chen J, Wu Z, Ding W, Gao S, Gao Y, Xu C: Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol. 2021, 178 (2): 239-261.
Talkar SS, Patravale VB: Gene Therapy for Prostate Cancer: A Review. Endocr Metab Immune Disord Drug Targets. 2021, 21 (3): 385-396.
Šamija I, Fröbe A: CHALLENGES IN MANIPULATING IMMUNE SYSTEM TO TREAT PROSTATE CANCER. Acta Clin Croat. 2019, 58 (Suppl 2): 76-81.
Akaza H, Hinotsu S, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Hirao Y, Murai M, Yamanaka H, Namiki M: The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J Urol. 2006, 176 (6 Pt 2): S47-9.
Abraham-Miranda J, Awasthi S, Yamoah K: Immunologic disparities in prostate cancer between American men of African and European descent. Crit Rev Oncol Hematol. 2021, 164 (): 103426.
de Vrij J, Willemsen RA, Lindholm L, Hoeben RC, Bangma CH, Barber C, Behr JP, Briggs S, Carlisle R, Cheng WS, Dautzenberg IJ, de Ridder C, Dzojic H, Erbacher P, Essand M, Fisher K, Frazier A, Georgopoulos LJ, Jennings I, Kochanek S, Koppers-Lalic D, Kraaij R, Kreppel F, Magnusson M, Maitland N, Neuberg P, Nugent R, Ogris M, Remy JS, Scaife M, Schenk-Braat E, Schooten E, Seymour L, Slade M, Szyjanowicz P, Totterman T, Uil TG, Ulbrich K, van der Weel L, van Weerden W, Wagner E, Zuber G: Adenovirus-derived vectors for prostate cancer gene therapy. Hum Gene Ther. 2010, 21 (7): 795-805.
Lee E, Ha S, Logan SK: Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells. PLoS One. 2015, 10 (10): e0141589.
['Nǔgbɛnúmɛ: dotóoxwé sín']
['Nǔkplɔnkplɔn kpo nǔsisɔ kpo sín azɔ̌ kɛɖɛ wɛ è nɔ wà dó tɛn ɛntɛnɛti tɔn elɔ jí, bo nɔ na wěɖexámɛ dotóoxwé tɔn alǒ azɔ̌ ɖevo lɛ mɛ ǎ.']
['È ɖó na zán nǔ e è kplɔ́n mɛ lɛ é dó ba azɔn ɖé alǒ azɔn ɖé sín wuntun alǒ dó gbɔ na ǎ, bɔ mɛ ɖěɖee jló na ba wěɖexámɛ dotóo tɔn lɛ é ɖó na yì mɔ dotóo e ɖó acɛ bo nɔ wà azɔ̌ ɖò dotóoxwé é ɖé.']
['Mi ni flín ɖɔ nǔ e è nɔ ylɔ ɖɔ "neural net" bo nɔ na xósin nú nǔkanbyɔ lɛ é ɔ, nǔ e nɔ nyí nǔjɛdo tawun é wɛ nyí nǔ ɖěɖee è nɔ ylɔ ɖɔ "numeric content" lɛ é. Ði kpɔ́ndéwú ɔ, mɛ nabi è mɔ azɔn ɖé na é.']
['Nɔ ba wěɖexámɛ dotóo towe tɔn alǒ dotóo ɖevo e ɖó nǔwukpikpé é tɔn dó azɔn ɖé wu hwebǐnu. Ma wɔn wěɖexámɛ dotóo tɔn lɛ gbeɖé ó, alǒ ma lin tamɛ kpɔ́n dó nǔ e a xà ɖò tɛn ɛntɛnɛti tɔn elɔ jí lɛ é wu ó. Enyi a lin ɖɔ azɔn baɖabaɖa ɖé ɖò xwi ɖí xá we wɛ hǔn, ylɔ 911 alǒ yì dotóoxwé e sɛkpɔ we hugǎn é tlolo. Tɛn ɛntɛnɛti tɔn elɔ alǒ nǔ e a nɔ zán lɛ é nɔ zɔ́n bɔ kancica dotóo-azinzɔnnɔ ɖé tɔn nɔ tíìn ǎ. BioMedLib, azɔ̌watɔ́ tɔn lɛ, alǒ mɛ ɖevo ɖebǔ e nɔ wlan nǔ dó tɛn ɛntɛnɛti tɔn elɔ jí lɛ é nɔ ɖè kúnnuɖenú ɖebǔ xlɛ́, bo tlɛ nɔ ɖɔ lɔ ǎ, dó nǔ e è ɖɔ ɖò fí lɛ é alǒ nǔ e è nɔ zán lɛ é wu.']
['Nǔɖògbɛ́jlatɔ́ lɛ']
['Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the DMCA) nɔ na acɛ mɛ e ɖó nǔɖokan yetɔn lɛ é bɔ ye na dó ba nǔɖe bo dó sixu mɔ nǔ e ye ɖó lɛ é ɖò Internet jí.']
["Enyi a ɖi nǔ ɖɔ nǔ ɖĕbǔ ɖò tɛn ɛntɛnɛti tɔn mǐtɔn jí alǒ azɔ̌wiwa mǐtɔn lɛ jí bo hɛn nǔ dó así nú mɛ ɔ, é xò nǔ dó acɛ nǔɖògbɛ́ towe lɛ wu ɔ, hwi (alǒ mɛ e nɔ kpé nukún dó wǔ towe é) sixu sɛ́ wɛn dó mǐ, bo byɔ ɖɔ mǐ ni ɖè nǔ ɖ'emɛ lɛ sín tɛn ɔ jí, alǒ ɖɔ mǐ ni sú ali dó mɛ."]
["È ɖó ná sɛ́ mɛ dó gbɔn email jí (e-mail è nɔ dó ɔ́' kpɔ́n 'Kɔntaktɔ́' ɔ́)."]
['DMCA byɔ ɖɔ ɖɔ nǔ elɔ lɛ ni nɔ akpáxwé nǔ e a ɖɔ é gbà acɛ dó nǔ é tɔn jí é: (1) xó dó azɔ̌ e ɖó acɛ dó nǔ é jí; (2) xó dó nǔ e ɖó acɛ dó nǔ é jí, kpo nǔ ɖevo e na zɔ́n bɔ mǐ na mɔ nǔ ɔ lɛ é kpo; (3) xó dó hwiɖée wu, ɖi adlɛsi towe, alokan towe kpo email towe kpo; (4) xó ɖɔ dó nǔ e wu a ɖi nǔ ɖɔ nǔ e ɖó acɛ dó nǔ e jí a ɖɔ é jí é kún nyí nǔ e ɖó acɛ dó nǔ é jí tɔn ɔ, alǒ mɛ e nɔ kpé nukún dó nǔ é tɔn wu é sín acɛ ó; ']
["(5) Ðɛ́ mɛ̀ è mi sɔ́ alɔ dó ɖ'así ná ɖò hwɛɖɔxɔsá ɔ́' è ɖó ná ɖó hwɛ̀ ɖɔ̀ xó è mi ɖɔ ɖò mɛ̀ è mi dó wèmá ɔ́ mɛ̀ ɔ́' sɔgbe bɔ̀ mi ɖó acɛ̀ bó ná dó ba ɖɔ è ní sú nǔ è è dó wèmá ɔ́ wú lɛ́ɛ sín axɔ́."]
['bɔ (6) alɔ wlanwlan mɛ e ɖó acɛ dó nǔ é tɔn alǒ mɛ e ɖó acɛ bo na wà nǔ dó wutu tɔn é tɔn. ']
['Nú a ma gɔ́ nǔ e ɖò jí lɛ é bǐ ǎ ɔ, é sixu zɔ́n bɔ è na lín có bo na dóhwɛ we.']
['Wǎ kpé mì']
['Mi kɛnklɛn bo sɛ́ nǔkanbyɔ mitɔn lɛ dó mǐ gbɔn e-mail jí.']
How to treat prostate cancer?
There are several treatment options available for prostate cancer, depending on the stage and aggressiveness of the cancer, as well as the patient's overall health and personal preferences.
Some common treatments include:
1. Active surveillance: This approach involves closely monitoring the cancer with regular checkups and tests, rather than immediately starting treatment.
It may be suitable for men with low-risk prostate cancer.
2. Surgery: A prostatectomy is a surgical procedure to remove the prostate gland.
It can be done through open surgery or laparoscopically (using small incisions and specialized tools).
3. Radiation therapy: This treatment uses high-energy radiation to kill cancer cells.
It can be delivered externally (from a machine outside the body) or internally (through implants placed near the tumor).
4. Hormone therapy: This treatment reduces the levels of male hormones (androgens) in the body, which can slow or stop the growth of prostate cancer.
It can be used alone or in combination with other treatments.
5. Chemotherapy: This treatment uses drugs to kill cancer cells.
It may be used for advanced prostate cancer that has spread to other parts of the body.
6. Immunotherapy: This treatment helps the immune system fight cancer.
It may be used for advanced prostate cancer that has not responded to other treatments.
7. Targeted therapy: This treatment targets specific genes or proteins that help cancer cells grow and survive.
It may be used for advanced prostate cancer that has not responded to other treatments.
8. Cryotherapy: This treatment uses extreme cold to freeze and kill cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
9. High-intensity focused ultrasound (HIFU): This treatment uses high-frequency sound waves to heat and destroy cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
10. Watchful waiting: This approach involves closely monitoring the cancer with regular checkups and tests, but not starting treatment unless symptoms appear or change.
It may be suitable for older men with slow-growing prostate cancer and other serious health conditions.
It is important to discuss all treatment options with a healthcare team to determine the best course of action for each individual case.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['E ɖò']
['BioMedLib nɔ zán ordinateur lɛ (algorithme nǔ kplɔnkplɔn mɔto tɔn lɛ) bo nɔ dó kàn nǔ byɔ mɛ lɛ bo nɔ lɛ́ na ye xósin.']
['Mǐ bɛ́ kpodo azɔwanú lanmɛ kpo lanmɛ kpo tɔn livi 35 e ɖò PubMed/Medline lɛ é kpo. Mǐ lɛ́ vɔ́ mɔ tɛn ɛntɛnɛti tɔn RefinedWeb tɔn lɛ.']
